IMMX Profile
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, specializes in the development of innovative tissue-specific therapeutics targeting oncology and inflammatory diseases. The company's primary focus is on advancing its lead product candidates through clinical trials to address significant unmet medical needs in cancer and chronic inflammatory conditions. Immix Biopharma's portfolio includes IMX-110, which is currently undergoing Phase 1b/2a trials for the treatment of soft tissue sarcoma and various solid tumors. This candidate represents a novel approach in oncology by targeting specific tissue environments to enhance therapeutic efficacy.
Additionally, the company is advancing IMX-111, a tissue-specific biologic designed for the treatment of colorectal cancers. This therapeutic aims to offer a targeted treatment option for patients with advanced colorectal cancer by focusing on the unique biological characteristics of the tumor. Another key candidate, IMX-120, is being developed as a tissue-specific biologic for managing ulcerative colitis and severe Crohn's disease, aiming to provide targeted relief for patients suffering from these chronic inflammatory conditions.
Immix Biopharma has established a clinical collaboration and supply agreement with BeiGene Ltd., focusing on a combination Phase 1b clinical trial that investigates the efficacy of IMX-110 in combination with BeiGene’s anti-PD-1 antibody, Tislelizumab. This partnership underscores the company's commitment to integrating its novel therapies with cutting-edge immuno-oncology treatments to enhance patient outcomes.
Founded in 2012 and headquartered in Los Angeles, California, Immix Biopharma continues to push the boundaries of medical innovation through its targeted therapeutic approaches. The company's efforts are dedicated to improving the lives of patients by developing advanced treatments for complex diseases, supported by strategic collaborations and a robust pipeline of clinical candidates.
|
